Kura Oncology (NASDAQ:KURA) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Kura Oncology (NASDAQ:KURA) in a research report report published on Thursday,Benzinga reports.

Other research analysts have also issued reports about the stock. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a research note on Friday, June 20th. Wall Street Zen lowered shares of Kura Oncology from a “buy” rating to a “hold” rating in a report on Friday, May 2nd. Mizuho cut their price target on Kura Oncology from $32.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, May 19th. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a report on Monday, April 28th. Finally, Barclays dropped their target price on Kura Oncology from $32.00 to $11.00 and set an “overweight” rating on the stock in a report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.50.

Kura Oncology Stock Down 1.2%

KURA stock opened at $5.73 on Thursday. The stock’s 50 day simple moving average is $6.18 and its 200 day simple moving average is $7.21. The company has a market cap of $496.05 million, a P/E ratio of -2.73 and a beta of 0.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.07 and a current ratio of 8.07. Kura Oncology has a fifty-two week low of $5.41 and a fifty-two week high of $23.48.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The firm had revenue of $14.11 million during the quarter, compared to analysts’ expectations of $39.08 million. On average, research analysts expect that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

Several institutional investors have recently modified their holdings of the business. BVF Inc. IL boosted its position in Kura Oncology by 202.0% in the first quarter. BVF Inc. IL now owns 7,754,129 shares of the company’s stock worth $51,177,000 after purchasing an additional 5,186,660 shares during the last quarter. RA Capital Management L.P. purchased a new position in shares of Kura Oncology in the 4th quarter worth about $38,769,000. Millennium Management LLC grew its position in Kura Oncology by 180.1% during the fourth quarter. Millennium Management LLC now owns 2,367,148 shares of the company’s stock valued at $20,618,000 after buying an additional 1,521,954 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in Kura Oncology during the fourth quarter worth about $8,518,000. Finally, Marshall Wace LLP purchased a new stake in Kura Oncology during the fourth quarter worth about $8,265,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.